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Abstract 
Background: The human immunodeficiency virus (HIV) cell reservoir is currently a main obstacle towards complete 
eradication of the virus. This infected pool is refractory to anti-viral therapy and harbors integrated proviruses that 
are transcriptionally repressed but replication competent. As transcription silencing is key for establishing the HIV 
reservoir, significant efforts have been made to understand the mechanism that regulate HIV gene transcription, and 
the role of the elongation machinery in promoting this step. However, while the role of the super elongation complex 
(SEC) in enhancing transcription activation of HIV is well established, the function of SEC in modulating viral latency is 
less defined and its cell partners are yet to be identified.
Results: In this study we identify fused in sarcoma (FUS) as a partner of AFF4 in cells. FUS inhibits the activation 
of HIV transcription by AFF4 and ELL2, and silences overall HIV gene transcription. Concordantly, depletion of FUS 
elevates the occupancy of AFF4 and Cdk9 on the viral promoter and activates HIV gene transcription. Live cell imag-
ing demonstrates that FUS co-localizes with AFF4 within nuclear punctuated condensates, which are disrupted upon 
treating cells with aliphatic alcohol. In HIV infected cells, knockout of FUS delays the gradual entry of HIV into latency, 
and similarly promotes viral activation in a T cell latency model that is treated with JQ1. Finally, effects of FUS on HIV 
gene transcription are also exhibited genome wide, where FUS mainly occupies gene promoters at transcription start-
ing sites, while its knockdown leads to an increase in AFF4 and Cdk9 occupancy on gene promoters of FUS affected 
genes.
Conclusions: Towards eliminating the HIV infected reservoir, understanding the mechanisms by which the virus 
persists in the face of therapy is important. Our observations show that FUS regulates both HIV and global gene tran-
scription and modulates viral latency, thus can potentially serve as a target for future therapy that sets to reactivate 
HIV from its latent state.
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Background
Early studies on the regulation of gene transcription of 
the proviral human immunodeficiency virus (HIV) have 
laid the foundations to our current understanding of how 
metazoan transcription elongation is regulated [1]. Fol-
lowing the recruitment of RNA Polymerase II (RNAPII) 
to the viral promoter and initiation of transcription, 
RNAPII associates with pause-inducing factors, DRB 
sensitivity inducing factor (DSIF) and negative elonga-
tion factors (NELF), and pauses at 25–50 nucleotides 
downstream of the mRNA transcription starting site 
(TSSs) [2–4]. Paused RNAPII remains stable with the 
nascent RNA, but can fully resume productive transcrip-
tion elongation upon recruitment of the super elongation 
complex (SEC) [1, 5–17]. For this step to be efficiently 
executed, the viral Trans-Activator of Transcription, Tat, 
acts as a master regulator of transcription elongation 
by tethering SEC to the HIV trans-activator response 
(TAR) stem-loop RNA on the viral short transcripts, 
and synergistically enhancing RNAPII pause-release and 
elongation. Within SEC two elongation factors, positive 
transcription elongation factor b (P-TEFb) and elonga-
tion factor for RNA polymerase II 2 (ELL2) are key com-
ponents. In P-TEFb, the Cdk9 kinase phosphorylates 
NELF and DSIF and antagonizes their inhibitory effects. 
Cdk9 also phosphorylates the serine 2 of the heptapep-
tide repeats (YSPTSPS) of the C-terminal domain (CTD) 
of RNAPII to enhance elongation of transcription. Simul-
taneously, ELL2 stimulates the processivity of RNAPII 
through suppressing its transient pausing [1, 2, 18–22]. 
While HIV recruits SEC via Tat, cells use other mecha-
nisms to bring the elongation machinery to their pro-
moter. The YEATS domain of ENL/AF9 brings SEC to 
chromatin  via  the human polymerase-associated factor 
complex (PAFc) [23, 24], while Brd4 recruits P-TEFb to 
acetylated chromatin, competing with Tat and inhibit-
ing HIV transcription [25, 26]. SEC also recruits P-TEFb 
to genes via interactions with Med26 of the mediator 
[27, 28]. In SEC, the AFF1-4 proteins of the AF4/FMR2 
family each act as a scaffold that bridges the complex to 
P-TEFb, forming a bi-functional complex that synergisti-
cally triggers transcription elongation by Pol II [29–33]. 
AFF proteins integrate within SEC as homo-dimers, or 
heterodimers, forming alternative complexes that also 
include a minor complex that potentially modulates HIV 
latency [34]. In recent years the implementation of high-
resolution genome-wide studies further strengthen the 
current model for RNAPII pausing, release and elonga-
tion, reinforcing what was already established for HIV [1, 
6, 16, 35–37]. Nevertheless, despite significant progress 
in understanding the molecular mechanisms that drive 
RNA pause-release and elongation of transcription, the 
mechanisms that control SEC functions are less defined 
and the search for its novel factors that can modulate its 
function is yet to be completed.
Besides being a model for studying eukaryotic tran-
scription control, there is a clinical significance in study-
ing transcription control of HIV. This step of the virus 
life cycle is a crucial event in establishing the latent HIV 
reservoir that harbors transcriptionally repressed virus 
and is primarily resides in resting CD4+ cells which are 
resistant to therapy [38, 39]. Thus, despite the introduc-
tion of antiretroviral therapy (ART), complete viral eradi-
cation remains out of reach [40–45]. While development 
of novel therapeutic strategies to eliminate the latent viral 
reservoir is a widely recognized goal, the knowledge on 
the molecular events that establish and maintain this 
state is limited. Extensive efforts are being made in opti-
mizing new approaches that will activate the virus with-
out affecting global cell activation and allow subsequent 
kill of infected cells by standard therapy [44, 46, 47].
Like other proteins of the FET family (FUS, EWSR1 
and TAF15; Ewing’s sarcoma (EWS) and TAF15 (TATA-
binding protein-associated factor), mutations in fused 
in sarcoma (FUS) are directly linked with protein aggre-
gation in amyotrophic lateral sclerosis (ALS) and fron-
totemporal dementia patients. FUS, was first identified 
in human myxoid and round cell liposarcomas as an 
oncogenic fusion protein with a stress-induced DNA-
binding transcription factor, CCAAT enhancer-binding 
homologous protein (CHOP, also known as GADD153 
or DDIT3) [48, 49]. FUS binds RNA and consists of low 
complexity (LC) motifs that are important for its func-
tions and for its ability to accumulate into phase separa-
tion structures [50–52]. FUS is also involved in regulating 
gene expression, coupling transcription to splicing via 
mediating interactions between RNAPII and U1 snRNP 
[53–56]. However, while FUS interactome has been 
extensively defined and overlaps with that of RNAPII and 
the transcription machinery, the functional significance 
of these interactions has yet to be established and a role 
for HIV transcription has not yet defined [57].  Knock-
down (KD) of FUS promotes a small increase in RNAPII 
traveling ratios at FUS-bound genes [54]. In addition, 
ChIP-seq and CLIP-seq analysis of RNAPII in FUS KD 
neuronal cells demonstrated that FUS is clustered around 
alternative polyadenylation (APA) sites of nascent RNA. 
The relative positioning of FUS and APA sites determines 
the length of the mRNA and the interactions of FUS with 
CPSF160 [58]. Finally, loss of FUS also leads to accumu-
lation of a phosphorylated Ser2 of the CTD of RNAPII 
near TSSs of genes that are enriched with FUS. Indeed, 
in the presence of FUS, the kinase activity of P-TEFb and 
Cdk12 toward the CTD is specifically inhibited [54].
In this study we employed immuno-purification (IP) 
followed by mass-spectrometry (MS) to pull-down cell 
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partners of AFF4. Our work identified FUS as a binding 
partner of AFF4. FUS silenced transcriptional activation 
from the HIV promoter both in the presence or absence 
of Tat expression, and restricted AFF4 and Cdk9 occu-
pancy on the viral promoter. Depletion of FUS expres-
sion exhibited reversal effects, and led to stimulation 
of HIV gene transcription. Importantly, knockout of 
FUS delayed the progressive entry of HIV into a latency 
state in infected T cells. In another T cell latency model, 
depletion of FUS expression also enhanced the activa-
tion effects of the BET bromodomain inhibitor JQ1. In 
addition, live imaging analysis demonstrated that FUS 
co-localized with AFF4 in the cell nucleus, exhibiting a 
punctuated expression pattern. Upon treating cells with 
Hexanediol, which disrupts phase separation structures, 
nuclear AFF4-FUS co-localization was disrupted, and 
proteins migrated to the cytoplasm. Finally, effects of FUS 
in modulating the transcription from the HIV promoter 
were also exhibited genome-wide, as elevated occupancy 
levels of AFF4 and Cdk9 were detected around gene pro-
moters that were upregulated following knockdown of 
FUS expression. Overall, we conclude that FUS silences 
HIV transcription and modulates viral latency through 
its recruitment to the host elongation machinery and 
restricting SEC/P-TEFb on the viral promoter.
Results
Identification of AFF4‑associating proteins in cells
To isolate cellular partners of AFF4 that potentially play 
a role in regulating the functions of SEC in gene tran-
scription, we took a proteomic approach and expressed 
full length HA-AFF4 (1–1163), or its truncated form 
HA-AFF4 (1–300) in HEK293T. We further conducted 
immuno-affinity purification (IP) of cell lysate using 
anti-HA antibody, and IP samples were resolved on 
SDS-PAGE and visualized by silver-staining  (Fig.  1b). 
In addition, samples were subjected to mass spectro-
metric (MS) analysis to identify the recovered proteins 
that co-purified with AFF4 [see Additional file 1: Figure 
S1—quantitative MS analysis; Additional file 2: Table S1 
(MS_AFF4-full length-FL) and Additional file 3: Table S2 
(MS_AFF4-300)]. Our analysis identified previously 
known partners of SEC such as Cdk9 and cyclin T1 that 
associated with full-length AFF4 and AFF4-(1–300), but 
not with the control cells that did not express HA-AFF4 
proteins, validating our purification scheme (Fig.  1b; 
Additional file 1: Figure S1). Interestingly, among the top 
hits that were recovered with full-length HA-AFF4, but 
not HA-AFF4-(1–300) or control cells, was an approxi-
mately 70 kDa protein that was identified by the MS anal-
ysis as Fused in Sarcoma, FUS (Fig. 1b; Additional file 1: 
Figure S1). FUS is a member of the FET protein family, 
and associates with RNAPII-CTD in an RNA-dependent 
manner [48, 54, 55, 59–61]. FUS has also been recently 
reported to localize within nuclear phase separated 
assemblies, while mutations in its N-terminal low com-
plexity (LC) regions (Fig.  1a) impair this distribution, 
linking FUS to the establishment of neurodegenerative 
disease like ALS [50, 52, 62–64].
We also aimed to confirm that FUS associates with 
AFF4 in cells, and to define the regions of AFF4 that 
interact with FUS. Flag-FUS and full length HA-AFF4 
or its truncated proteins including HA-AFF4 (1–850) 
(1–650), (1–400), (1–300) were over-expressed in cells, 
and cell lysates were subjected to IP with HA-antibody, 
followed by western blotting with anti-Flag antibody 
(Fig. 1c). Our analysis demonstrated that while HA-AFF4 
full-length (1–1163) and truncated proteins HA-AFF4 
(1–850) (1–650) and HA-AFF4 (1–400) associated with 
Flag-FUS, a shorter form of HA-AFF4 (1–300) could 
not associate with Flag-FUS (Fig. 1c). We conclude that 
N-terminal residues of AFF4 between positions 300–400 
are required for association with FUS.
FUS inhibits HIV transcription from the viral promoter
Much of our current understanding of the functions of 
P-TEFb and SEC comes from pivotal work on the con-
trol of transcription elongation of HIV, which is heavily 
depended on the activity of these two transcription elon-
gation complexes [11, 38]. To elucidate the role of FUS 
in HIV transcription, we initially examined its effects on 
AFF4 and ELL2-mediated activation of HIV transcrip-
tion in the presence or absence of FUS. Previous results 
reported that AFF4 activates transcription from the HIV 
promoter and cooperates with ELL2 to synergies basal 
but not Tat-dependent HIV transcription [22]. Thus, the 
LTR-Luciferase (Luc) reporter cassette was expressed in 
HEK cells with AFF4 or ELL2, monitoring their effects 
on HIV LTR gene transcription (Fig. 2). Our results con-
firmed that ELL2 activated HIV transcription from the 
LTR promoter fourfold, while AFF4 was more potent and 
stimulated LTR-Luc transcription 10 fold. Co-expression 
of both ELL2 and AFF4, further enhanced HIV gene 
transcription up to 15 fold relative to basal activation. 
Significantly, expression of FUS, inhibited AFF4-medi-
ated activation of HIV gene transcription twofold. FUS 
also exhibited silencing effects on HIV transcription in 
the presence of both AFF4 and ELL2 (Fig. 2).
We next aimed to monitor the effects of FUS on over-
all HIV gene transcription in Jurkat T cells, which are a 
more natural cell target of HIV. Western Blot analysis 
confirmed FUS expression in these cells (Fig. 3a, lane 1; 
lane 2 monitored Flag FUS expression). We then ana-
lyzed the role of FUS in regulating HIV gene transcrip-
tion in Jurkat (J)-LTR-luciferase T cells (J-LTR-Luc) that 
harbor an integrated luciferase reporter gene under the 
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control of the HIV promoter (Fig.  3b). J-LTR-Luc cells 
were transduced with lentivirus that drive the expression 
of Flag-FUS and a GFP reporter gene that was translated 
via an IRES sequence. Transduced cells were further 
sorted by FACS based on their GFP expression—gener-
ating J-LTR-Luc-FUS cells and their Flag-FUS expression 
was validated by western blotting with anti-Flag antibody 
(Fig.  3c). In addition, we also generated J-LTR-Luc cells 
that stably expressed a Flag-FUS mutant that does not 
bind RNA, as it consists of arginine to serine mutations 
in RGG1 2 and 3 of FUS (J-LTR-Luc-FUS SGG4) [65]. 
Analysis of HIV LTR driven luciferase activity in con-
trol J-LTR-Luc and in J-LTR-Luc FUS cells demonstrated 
that ectopic expression of FUS moderately inhibited gene 
transcription from the HIV promoter (twofold), relative 
to control J-LTR-Luc cells that did not over-expressed 
FUS (compare gray bars to white bars in J-LTR-Luc FUS 
cells relative to control J-LTR-Luc cells; Fig. 3b). Expres-
sion of the SGG4 FUS mutant in J-LTR-Luc cells, did 
not repressed HIV-mediated luciferase activity and 
Fig. 1 Characterization of AFF4-associated proteins. a Schematic domain organization of human AFF4 and FUS proteins. AFF4 serves as a scaffold 
for the assembly of SEC subunits including the elongation transcription complexes ELL1/2 and P-TEFb [83]. At its N-terminal region it consists the 
P-TEFb binding domain (orange); the ELL domain (yellow); ENL/AF9 (black); and a C-terminal motif (orange). In FUS, the N-terminal of the protein 
exhibits low sequence complexity (blue). The RGG domains contain a triplet repeat motif of arginine–glycine–glycine (green). FUS also contains 
an RNA-recognition motif (RRM) (red), a zinc-finger domain (ZnF) gray), and a proline–tyrosine nuclear localization signal (PY–NLS; dark red) [55]. 
b Purification of AFF4 protein partners by affinity purification. Control HEK293T cells, or cells expressing either Full length HA-AFF4 (1–1163) or 
its truncated form HA-AFF4 (1–300) were subjected to HA-epitope-tagged immuno-purification (IP) with anti-HA antibody. IP samples were 
separated by SDS-PAGE and visualized by silver staining. Cellular partners of HA-AFF4 proteins were also identified by tandem mass spectrometry. 
Previously confirmed SEC/P-TEFb partners as well as newly identified partners like FUS were recovered by our MS analysis (also see Additional file 1: 
Figure S1, Additional file 2: Table S1 and Additional file 3: Table S2 for quantitative analysis of the MS results). Red asterisks indicate potential novel 
AFF4 partners, which FUS is one of them: Blue asterisks point to the full-length and truncated AFF4 (1–300) proteins. c N-terminus region of AFF4 
associates with FUS in cells. Western blot analysis of immuno-precipitation (IP) samples defining the regions of AFF4 that mediate association with 
the FUS in cells. Lysates from HEK293T cells expressing Flag-FUS and the indicated HA-AFF4 proteins were IP with anti-HA IgG. IP. IP and input (5%) 
samples were analyzed by SDS-PAGE followed by western blot analysis with anti-HA or anti Flag antibodies
Page 5 of 19Krasnopolsky et al. Retrovirology           (2019) 16:16 
transcription levels returned to those displayed by the 
wild type J-LTR-Luc control cells (black bars versus white 
bars), implying that the RNA binding of FUS is required 
for the ability of FUS to repress HIV transcription.
FUS effects were also tested in Jurkat (J)—LTR-Tat-
Luc cells that stably express the Tat protein under the 
HIV LTR promoter. To generate these cells, J-LTR-Luc 
were transduced with lentivirus encoding Tat-BFP (LTR-
HA-Tat-BFP), following by cell sorting based on BFP 
expression. J-LTR-Tat-Luc cells were further transduced 
with lentivirus expressing Flag-FUS (or FUS-SGG4) 
as described above, to generate J-LTR-Tat-FUS J-LTR-
Tat-Luc FUS SGG4. FUS expression was confirmed by 
western blotting with anti-Flag antibody (Fig.  3c). As 
expected, Tat expression enhanced gene transcription 
activity from the HIV promoter to about 22 fold relative 
to control J-LTR-Luc cells that did not express Tat (com-
pare white bars; Fig.  3b). In contrast, following ectopic 
expression of FUS, Tat transactivation was repressed 
about threefold relative to J-LTR-Tat-Luc (compare white 
bars relative to gray bars of J-LTR-Tat-Luc-FUS; Fig. 3b). 
No inhibition of HIV transcription was observed upon 
ectopic expression of the FUS-SGG4 mutant (Fig.  3b; 
black bar). To verify that the effects of FUS on HIV tran-
scription were direct and not stem from different levels 
of Tat expression we also monitored HA-Tat expression 
levels by western blotting, confirming equal HA-Tat 
expression levels in J-LTR-Tat-Luc and J-LTR-Tat-Luc-
FUS cells, (Fig. 3d). We thus conclude that FUS inhibited 
both basal (Tat independent) and Tat dependent HIV 
transcription.
Knockout of FUS expression activates gene transcription 
from the HIV promoter
We next depleted the expression of endogenous FUS in 
Jurkat (J)-LTR-Luc, using CRISPR/Cas9 (Fig.  4). J-LTR-
Luc were transduced with lentivirus that drive the 
expression of Cas9 and several small guides sgRNA that 
specifically target FUS. Cells were subjected to puro-
mycin selection, and knockout (KO) of FUS expression 
was verified by western blotting, as well as by genomic 
sequencing (Fig.  4b, shows a representative WB of a 
J-LTR-Luc-FUS KO clone; sequence analysis near the 
sgRNA position site of two representative clones are also 
shown in Fig. 4d). Control J-LTR-Luc cells that encoded 
Cas9 and a control scrambled sgRNA were also gener-
ated. As shown in Fig.  4, upon FUS KO, transcription 
from the LTR HIV promoter in J-LTR-Luc FUS KO was 
upregulated fourfold relative to control J-LTR-Luc cells 
that expressed scrambled sgRNA (compare the black 
bar of control cells to the gray bar of J-LTR-Luc-FUS 
KO cells—Fig. 4a). Effects of FUS KO on gene transcrip-
tion from the HIV LTR promoter were also tested in the 
presence of Tat. Herein, J-LTR-Luc FUS KO were fur-
ther transduced with lentivirus expressing HA-Tat BFP 
to generate J-LTR-Tat-FUS KO cells. Tat expression was 
confirmed by western blotting (Fig.  4c). As expected, 
upon Tat expression, HIV gene transcription in J-LTR-
Tat Luc cells was stimulated up to 20 fold relative to 
control J-LTR-Luc cells (compare J-LTR-Luc and J-LTR-
Tat-Luc black bars; Fig.  4a). Upon FUS KO, Tat trans-
activation was also increased, reaching similar levels as 
in the control cells that expressed the scramble sgRNA. 
J-LTR-Tat-Luc FUS KO exhibited a 24 fold increase in 
HIV transcription relative to J-LTR-Luc control cells 
(gray bar in J-LTR-Tat-Luc-FUS KO, relative to black bar 
in J-LTR-Luc). We thus conclude that despite loss of FUS, 
Tat transactivation still reached optimal levels.
To further strengthen the inhibitory effects of FUS 
on HIV transcription, we examined whether the silenc-
ing of HIV gene transcription by FUS in J-LTR-Luc-FUS 
KO cells could be reversed by re-introducing exogenous 
FUS. J-LTR-Luc FUS KO cells were thus transduced 
with increasing MOI of lentivirus that drive the expres-
sion of Flag-FUS-IRES-GFP. Cells were sorted based on 
their GFP expression by FACS and were grouped based 
on their GFP intensity. Sorted cells were then harvested 
and subjected to luciferase assay, monitoring effects on 
HIV gene transcription (Fig.  4e). As seen above, FUS 
KO activated HIV transcription—fivefold (Fig.  4e, lane 
2). Increasing expression levels of FUS in J-LTR-FUS KO 
Fig. 2 FUS inhibits activation from the HIV promoter by AFF4 and 
ELL. Cells expressing AFF4, ELL2 or both proteins were monitored for 
their ability to activate the HIV promoter in the presence or absence 
of FUS. Indicated concentrations of FUS expression plasmid were 
also used. Relative transcription corresponds to luciferase readings 
relatively to control cells that express the LTR-Luc - set to 1. Readings 
are representative of three independent experiments. The error bars 
represent mean ± SD from three independent reactions
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cells led to inhibition of viral transcription (Fig. 4e, lanes 
3–5).
FUS associates with the HIV promoter through TAR 
and restricts the occupancy of AFF4 and Cdk9 on the HIV 
promoter
Through its basic residues RGG/RRM motifs, FUS binds 
RNA and plays a role in association with the CTD of 
RNAPII to modulate gene transcription [54, 65]. How-
ever, FUS binding to RNA is non-specific as previous 
reports determine that it exhibits a wide-range affin-
ity to its RNA substrates and possess a general nucleic 
acid binding activity binding [60, 65]. We thus tested the 
association of FUS to HIV TAR using RNA-immunopre-
cipitation (RIP)-qPCR analysis in J-LTR-Luc-FUS cells 
that stably over-express Flag-FUS (Fig.  5). Cell lysates 
were immuno-precipitated with anti-Flag or control 
antibodies, and RNA that was co-immuno-precipitated 
material was extracted, reverse transcribed and ampli-
fied by qPCR using specific primers for TAR. GAPDH 
RNA was similarly quantified as control (Fig.  5). Our 
analysis demonstrated that FUS associated with TAR in 
HIV transduced cells. However, these interactions were 
not specific, as FUS also associated with GAPDH RNA 
to similar levels. RIP qPCR experiments were also per-
formed in J-LTR-Tat Luc FUS. Upon Tat expression, FUS 
association with TAR was slightly, but statistically signifi-
cant, inhibited, while such inhibition was not displayed 
when FUS-GAPDH interactions were monitored (Fig. 5). 
Moreover, our RIP analysis with a FUS mutant that does 
not bind RNA (FUS SGG4) demonstrated that its asso-
ciation with the TAR HIV promoter were close to back-
ground levels (Additional file 1: Figure 2SA). Finally, a Tat 
mutant that does not bind TAR (Tat 1–48) demonstrated 
that it cannot compete with FUS on association with 
TAR RNA (Additional file 1: Figure S2B).
Fig. 3 FUS silences gene transcription from the HIV promoter. a FUS expression in Jurkat cells. Western Blotting analysis confirming endogenous 
expression of FUS in J-LTR-Luc cells, (lane 1) and expression of Flag-FUS in J-LTR-Luc-FUS cells (lane 2) using FUS IgG. b FUS silences transcription 
from the HIV promoter. Jurkat (J)-LTR-Luc and J-LTR-Tat-Luc cells that stably express Tat, were monitored for their LTR luciferase readings in the 
absence or presence of FUS expression (gray bars), or its SGG4 mutant that does not bind RNA (black bars). Relative transcription corresponds 
to luciferase readings relatively to control Jurkat cells that express the LTR-Luc reporter gene - J-LTR-Luc - set to 1 (white bars). Readings are 
representative of three independent experiments. The error bars represent mean ± SD from three independent reactions. Asterisks indicate levels of 
statistical significance as calculated by two-tailed student T test (**p ≤ 0.01). c Western Blot analysis confirming Flag-FUS (lanes 2–3) and SGG4 (5–6) 
expression in J-LTR-Luc and J-LTR-Tat-Luc cells using anti-Flag IgG. Lanes 1 and 3 represent cells that do not express Flag-FUS. Lower panel represent 
tubulin western blot for monitoring loading control. d Western Blot analysis to confirm equal expression of Tat in J-LTR Tat-Luc and J-LTR-Tat-Luc-FUS 
(lanes 2 and 3) and compared to J-LTR -Luc that do not express Tat (lane 1). Lower panel represent tubulin western blot for loading control
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As our results suggested that FUS associates with 
AFF4 and also interacts with TAR, we next monitored 
FUS occupancy on the HIV promoter by employing 
quantitative chromatin IP (ChIP) - qPCR - in J-LTR-Luc 
or J-LTR-Tat Luc cells (Fig.  6). ChIP material was iso-
lated from these cells and subjected to IP with anti-FUS 
Fig. 4 Depletion of FUS expression activates transcription of HIV. a Depletion of FUS activates HIV gene activation. Luciferase readings were 
determined in J-LTR-Luc FUS KO and J-LTR-Tat-FUS KO cells, where FUS expression was depleted. To obtain these cells, Jurkat (J)-LTR-Luc were 
transduced with lentivirus driving the expression of Cas9/sgRNA (FUS specific) and following puromycin drug selection, mono-clonal cells where 
FUS expression was knockout (KO) were obtained (J-LTR-Luc-FUS KO; gray bar). Control cells were similarly generated, where their CRISPR/sgRNA 
vector harbored a scrambled sgRNA (black bar). To generate J-LTR-Tat-FUS KO, a selected J-LTR Luc FUS KO clone was further transduced with 
lentivirus expressing HA-Tat-BFP, and cells were sorted based on their BFP expression (black bar). Luciferase activity was monitored 48 h post 
transduction according to the manufacturer protocols. Data are presented relatively to luciferase readings in control cells J-LTR-Luc—set to 1, and 
are representative of three independent experiments. The error bars represent mean ± SD from three independent reactions. Asterisks indicate 
levels of statistical significance as calculated by two-tailed student T test (**p ≤ 0.01). When asterisks are not shown, no statistically significant 
difference was observed. b Western Blot analysis of J-LTR-Luc FUS KO cells using FUS antibody, confirming depletion of FUS expression (lane 2). 
Endogenous expression of FUS in control J-LTR-Luc cells is also presented (ct; lane 1). c Western Blot analysis of J-LTR-Tat-Luc FUS KO cells confirming 
HA-Tat expression. J-LTR-Luc-FUS KO cells were transduced with lentivirus that drive the expression of HA-Tat. Cells were sorted based on their BFP 
expression (linked to Tat via IRES). Sorted cells were then harvested and subjected to luciferase assay and western blotting using an HA IgG. Tat 
expression in control J-LTR-Tat Luc cells was also monitored (lane 1). d Characterization of J-LTR-Luc-FUS knockout clones. Genotyping of genomic 
DNA isolated from the two J-LTR-Luc-FUS KO clones, where the gene encoding for FUS was disrupted following the introduction of Cas9/sgRNA. 
Presented is the nucleotide and amino acid residues of FUS around the region where the sgRNA oligos was located. Two independent clones are 
presented (a and b), where deletions were generated around the sgRNA sequence targets. a—in Clone #11 two sgRNA were used (sgRNA 1 and 2) 
and generated a 122 bp gap; b—in Clone #1, a single sgRNA was used (sgRNA 1) formed a short deletion as well. e Overexpression of FUS restores 
HIV gene silencing in FUS KO cells. J-LTR-Luc-FUS KO cells were transduced with increasing MOI of lentivirus that drive the expression of Flag-FUS. 
Cells were sorted based on their GFP (linked to FUS via IRES) intensities to obtain different levels of FUS expression in cells. Sorted cells were further 
grown, harvested and subjected to luciferase assay according to the manufacturer protocol. Results are presented relatively to luciferase readings 
in J-LTR-Luc control cells that express scrambled sgRNA—set to 1. Error bars show mean ± SD from three independent reactions. Asterisks indicate 
levels of statistical significance as calculated by two-tailed student T test (p < 0.01). Also presented is a western blot verifying increasing amounts 
of FUS expression. Control J-LTR-Luc express endogenous FUS (lane 1), while J-LTR-Luc-FUS KO cells do not (lane 2). J-LTR-FUS-KO that express 
increasing concentrations of Flag FUS are also presented (lanes 3–5)
Page 8 of 19Krasnopolsky et al. Retrovirology           (2019) 16:16 
or control anti-rabbit antibodies, and qPCR analysis was 
performed using primers located on the HIV promoter 
near its TSS (Fig. 6). Our analysis suggested that FUS was 
specifically recruited to the HIV promoter, as a control 
IgG showed a very low ChIP qPCR signal. Moreover, the 
role of TAR on FUS occupancy was also determined by 
comparing FUS occupancy on an integrated viral pro-
moter that is deleted with TAR (delta TAR). Our results 
showed that TAR deletion lowered the levels of FUS 
occupancy on the HIV promoter relatively to FUS levels 
when (Fig. 6a + b). Moreover, FUS occupancy on an HIV-
LTR TAR promoter was reduced in J-LTR-Tat FUS cells 
that express Tat, implying of the ability of Tat to compete 
with FUS on its occupancy on the HIV promoter as it 
potentially masks the RNA target (Fig. 6a). No effects of 
Tat on FUS occupancy were detected when a delta-TAR 
promoter was used in the qPCR assay as Tat cannot bind 
the HIV promoter without TAR (Fig.  6b). We further 
examined by ChIP-qPCR the effects of FUS in recruit-
ing AFF4 and P-TEFb to the HIV promoter. Experiments 
were performed in J-LTR-FUS KO cells that transiently 
expressed either HA-AFF4-FL (full length), or HA-AFF4 
(1–300) using anti-HA or control antibodies (Fig.  6c). 
Our results showed that KO of FUS expression elevated 
the occupancy of full-length AFF4 on the viral pro-
moter compared to control cells that expressed endog-
enous FUS. In addition, regardless of FUS expression, 
HA-AFF4-(1–300) could not occupy the HIV promoter 
(Fig. 6c). The occupancy of Cdk9 in Jurkat (J) -LTR-Luc, 
or J-LTR-Luc-FUS KO was also monitored by ChIP-
qPCR using anti-Cdk9 or control antibodies (Fig.  6d). 
Our analysis demonstrated that in J-LTR-Luc-FUS KO 
cells, upon FUS KO, Cdk9 occupancy on the HIV pro-
moter was elevated, relative to that in control J-LTR-Luc 
cells. We conclude that FUS modulates SEC/P-TEFb 
occupancy on the HIV promoter, and its KO leads to an 
increase of SEC/P-TEFb occupancy, resulting in the acti-
vation of viral transcription.
Depletion of FUS expression enhances the reactivation 
of HIV latency by JQ1
Our results indicate that FUS limits the occupancy of 
AFF4 and P-TEFb on the HIV promoter (Fig.  6) and 
inhibits viral gene transcription (Figs.  2, 3). As repres-
sion of HIV transcription is key for the establishment and 
maintenance of the HIV latent reservoir, we examined 
if depletion of FUS expression affects HIV latency. For 
this J-LTR-Luc cells that harbor an integrated LTR-Luc 
reporter, or J-LTR-Luc FUS KO cells were transduced 
with a pseudotyped HIV encoding virus (pHR-GFP). At 
day 2 post infection, control or FUS KO cells were sorted 
based on their GFP expression, and GFP(+) cells were 
further cultured to allow them to progressively enter 
latency, while monitoring their GFP expression at the 
indicated time post transduction (Fig.  7a). At 60 d.p.i. 
(days post infection) both control J-LTR-Luc and J-LTR-
Luc-FUS-KO cells entered latency, as detected by the 
gradual decrease in the GFP expression (Fig. 7a). Signifi-
cantly, J-LTR-Luc-FUS KO cells exhibited a delay in their 
entry into viral latency, compared with control J-LTR-Luc 
cells. Differences in GFP expression between the two cell 
types were visible as early as 20 d.p.i and at 60 dpi, 80% 
Fig. 5 FUS non-specifically associates with TAR RNA. Jurkat (J)-LTR-Luc-FUS and J-LTR-Tat-FUS cells that harbor the integrated HIV-LTR-Luc 
reporter and also over-express Flag-FUS were subjected to RNA immunoprecipitation (RIP) qPCR. Cell lysate was immune-precipitated with either 
anti-Flag-IgG (black bars), or control non-specific IgG (gray bars). RNA was then extracted from IP or input (10%) samples with Trizol, followed by 
reverse transcription and amplification with primers that target the indicated RNA. qPCR reactions on samples were performed in triplicates and 
presented as percentage from input ChIP material. The error bars represent mean ± SD of the triplicate independent qPCR reactions. Asterisks 
indicate levels of statistical significance calculated by two-tailed student T test (p < 0.01)
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of LTR-Luc-FUS KO cells expressed HIV-GFP, while only 
40% of control cells expressed GFP (Fig.  7a). To ensure 
that indeed the cells entered latency, pooled GFP(−) 
cells from either J-LTR Luc or J-LTR-Luc FUS KO were 
re-sorted at day 60, and the isolated GFP(−) cells were 
treated with either Phorbol 12-myristate 13-acetate  -  a 
PKC agonist (PMA), or JQ1 - a BET bromodomain inhib-
itor and analyzed by FACS for GFP expression (Fig. 7b). 
Our results verified that at 60 d.p.i. cells did not express 
the LTR-GFP. However, following treatment with HIV 
activators, PMA or JQ1, expression of the integrated 
LTR-GFP was elevated, implying the activation of latent 
Fig. 6 FUS occupies the HIV promoter and its depletion enhances the recruitment of SEC and P-TEFb to the viral promoter. a + b FUS occupancies 
the HIV promoter. ChIP material was isolated from Jurkat (J)-LTR-Luc or J-LTR-Tat-Luc cells, where the LTR promoter either harbors TAR (a), or 
consists of a LTR-delta TAR (b). Cells were subjected to FUS-IP using FUS antibody. qPCR on IP samples was conducted with a pair of primers located 
on the HIV promoter and signals were presented as percentage from input. The error bars represent mean ± SD from three independent qPCR 
reactions. Asterisks indicate levels of statistical significance calculated by two-tailed student T test (p < 0.01). c FUS restricts AFF4 occupancy on the 
HIV promoter. ChIP material from Jurkat (J)-LTR-Luc cells and J-LTR-Luc-FUS KO, where FUS expression was depleted and also express HA-AFF4 or 
HA-AFF4-300, was subjected to immune-precipitated with anti-HA-antibody or control antibody followed by qPCR with primers located on the HIV 
promoter. Data are presented as percentages of the input DNA, and representatives of three independent experiments. The error bars represent 
mean ± SD from three independent qPCR reactions. Asterisks indicate levels of statistical significance as calculated by two-tailed student T test 
(**p ≤ 0.01). d FUS modulates Cdk9 occupancy on the HIV promoter. ChIP-qPCR analysis of J-LTR-Luc, or J-LTR-Luc-FUS-KO cells were performed 
by using anti-Cdk9 IgG. As control, IP on ChIP material was also performed with non-specific IgG. qPCR analysis was performed with the primers 
located on the HIV promoter (a). Signals present percentage from input DNA, and results are representative of three independent experiments. The 
error bars represent mean ± SD from three independent qPCR reactions. Asterisks indicate different levels of statistical significance as calculated by 
two-tailed student T test (**p ≤ 0.01)
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HIV in these cells (for J-LTR-Luc cells  - up to 25% with 
PMA, and 17% with JQ1; for J-LTR-Luc FUS KO cells 
32% with PMA and 22% with JQ1). Overall, we conclude 
that KO of FUS expression in J-LTR Luc that harbor inte-
grated HIV delays viral entry into a latency state.
We further examined the effects of FUS on reactiva-
tion of HIV in a different latency cell model - 2D10. 
These cells express an attenuated form of Tat (H13L) that 
activates in cis the expression of an integrated d2GFP 
reporter inserted in place of the nef gene and is regulated 
under the control of the viral LTR promoter [66]. 2D10 
were transfected with either a scrambled, or FUS-specific 
siRNA and knockdown (KD) of FUS was verified by west-
ern blotting. Cells were also analyzed for their HIV gene 
expression by FACS (Fig. 7c). Our results showed that in 
2D10 cells where FUS expression was KD, there was a 
slight increase in expression levels of HIV-d2GFP, relative 
to control 2D10 cells that expressed scrambled siRNA, 
indicating a possible activation of latent cells (Fig. 7c). We 
also monitored the effects of FUS KD on latent HIV, fol-
lowing reactivation of cells with JQ1—a Bromodomain 
domain (BET) inhibitor with a latency reversing activity 
(LRA) of HIV [47, 67, 68]. At 0.2 μM or 0.4 μM of JQ1 
treatment, 2D10-FUS KD cells exhibited higher expres-
sion levels of their integrated d2GFP reporter compared 
to control 2D10 cells, indicating that upon FUS KD sen-
sitizes, the activating activity of JQ1 on latent HIV is syn-
thesized (twofold for 0.2 μM; Fig. 7c). To further confirm 
Fig. 7 Knockdown of FUS expression enhances reactivation of HIV latency by JQ1. a Depletion of FUS delays the establishment of HIV latency. 
J-LTR Luc (red line) or J-LTR-Luc FUS KO cells (green line) were transduced with pseudotyped HIV-pNL4-GFP virus, where a GFP reporter in inserted 
instead of the env gene. Cells were sorted based on their GFP expression (day 0 post infection) and further grown for the indicated time days post 
infection to allow them to gradually enter viral latency. GFP expression was monitored at the indicated time points by FACS analysis as a reference 
for entry into viral latency. b Reactivation of latent cells. At 60 d.p.i., transduced J-LTR Luc or J-LTR-Luc FUS KO cells were sorted based on their GFP 
expression for GFP(−) cells. Cells were then treated for 24 h. with either PMA or JQ1 activators, at the indicated concentrations, and subjected to 
FACS analysis to monitor their GFP expression, which corresponds to viral reactivation. Error bars indicate mean ± SD from triplicates. c Knockdown 
of FUS expression enhances reactivation of HIV latency by JQ1. 2D10 latent cells were introduced with either FUS-specific or scrambled (control) 
siRNA oligos. 72-h post transfection, cells were treated with JQ1 in the indicated concentrations. 24 h post treatment HIV gene expression was 
analyzed by FACS, monitoring d2GFP. d HIV RNA levels are elevated upon FUS KD in 2D10 cells and treatment with JQ1. Control 2D10 latent cells 
(harboring scrambled siRNA), or cells where FUS expression was depleted by specific siRNA were treated with 0.2 μM JQ1 and subjected to RT-qPCR 
with specific primers amplifying the indicated HIV gene targets - Gag and Rev. Results are presented relative to GAPDH mRNA levels. Also presented 
is a western blot confirming KD of FUS expression
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our results, early multiply spliced Rev and late un-spliced 
Gag mRNA levels were quantified by RT-qPCR in con-
trol or FUS KD 2D10 cells treated with 0.2 μM JQ1. We 
demonstrated that while 2D10 cells that were not treated 
with JQ1 displayed undetectable levels of HIV mRNA, 
the combination of FUS KD and treatment with JQ1 led 
to an increase in HIV Gag and Rev mRNA levels, relative 
to control cells that expressed FUS (Fig. 7d; twofold). We 
conclude that FUS modulates HIV latency and poten-
tially promotes this state, while its KD enhances the reac-
tivation of latent HIV following treatment with JQ1.
FUS and AFF4 co‑localize within nuclear condensates
FUS is an RNA/DNA binding protein, which is primarily 
localized in cells to the nucleus and forms ribonucleopro-
tein, liquid-like nuclear droplets that phase separate from 
their environment. The formation of these liquid mem-
brane-less condensates is mediated through the N-termi-
nal low complexity (LC) region of FUS, which exhibits a 
disordered structure and contains multiple repeats of a 
S/GYS/G motifs [50]. Upon stress, FUS rapidly shuttles 
between these liquid compartments in the nucleus and 
the cytoplasm. With time, or as a result of specific muta-
tions, FUS liquid droplets convert to an aggregated state, 
which is reminiscent of the pathological state seen in 
ALS patients [50–52, 62]. As FUS associates with AFF4 
in cells, we employed live-imaging analysis to visualize 
their cell distribution and to determine if the proteins 
co-localize (Fig. 8). Cells were expressed with AFF4-BFP, 
or FUS-GST fusion proteins (Fig.  8a + b), or with both 
proteins (Fig. 8c), and those which expressed low inten-
sity of protein fluorescence were monitored. Our imag-
ing analysis confirmed previous reports showing that in 
cells, FUS exhibits a nuclear punctuated expression pat-
tern that correspond phase separation structures (Fig. 8a) 
[69]. Moreover, AFF4 which also harbors low complex-
ity motifs, was also localized to the nucleus and like FUS 
exhibited a granular expression pattern [70] (Fig.  8b). 
Upon expressing both proteins, AFF4 and FUS were co-
localized into the nucleus, and displayed a condensed 
and punctuated expression arrangement (Fig.  8a–c). 
Treating cells with 15% 1,6-hexanediol, which is known 
Fig. 8 Co-localization of AFF4 and FUS within nuclear condensates. Live-imaging analysis of cells expressing either FUS-GFP (a), AFF4-BFP (b) or 
cells co-expressing both proteins (c). Cells were also treated with 1-6-Hexanediol to disrupt nuclear liquid-like condensates (d–f). A low resolution 
image is shown for each condition, where labeled cells are also displayed in a higher magnification. Cells were examined under an Olympus FV1000 
confocal microscope. Nuclei were stained with DRAQ5 dye (magenta; 1:1000 dilution)
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to perturb weak hydrophobic interactions and disassem-
ble membrane-less structures with liquid-like properties, 
partially disrupted the nuclear punctuated expression 
pattern of FUS and AFF4 (Fig. 8d + f ). In particular, treat-
ment also led to FUS-AFF4 protein migration to the 
cytoplasm, where proteins lost their punctuated expres-
sion pattern (Fig. 8d + f ). We conclude that FUS co-local-
ized with AFF4 within the nucleus and exhibits granular 
condensate expression patterns, similar to phase separa-
tion organelles [71].
FUS modulates SEC occupancy genome‑wide
We next tested if the silencing effects of FUS on the occu-
pancy of SEC and P-TEFb that were shown for the HIV 
promoter, were also evident on a genome wide scale. 
ChIP-seq analysis confirmed that like in the case of HIV, 
FUS is enriched around TSSs at coding genes (40) (Addi-
tional file  1: Figure S3A). This analysis called for 4141 
FUS peaks, of them > 55% are located around TSSs. Inter-
estingly, FUS is also recruited to exons (12.1%), introns 
(14.51%), termination sites (3.4%) and intergenic regions 
(14.41%) (Additional file 1: Figure S3B). We next analyzed 
publicly published RNA-seq datasets and defined 4194 
genes that are affected upon depletion of FUS expres-
sion [29, 54]. Among these genes, 2236 were upregulated 
similarly to the tendency detected for HIV, while 1958 
were down-regulated. 11,484 genes were found to be 
unaffected following FUS depletion of expression (Addi-
tional file  1: Figure S3C). We focused our analysis on 
FUS affected loci (in FUS KO cells), and combined these 
datasets with the ChIP-seq analysis describing the occu-
pancy of SEC and P-TEFb (AFF4 and Cdk9; [29, 54]). We 
found that both up and down-regulated genes (upon FUS 
depletion) exhibited higher occupancy levels of Cdk9 and 
AFF4 on their promoters, relative to unaffected gene pro-
moters (Fig.  9). Of the FUS affected genes, the upregu-
lated genes exhibited slightly but statistically significant 
higher occupancy levels of both AFF4 and Cdk9 upon 
FUS depletion, relative to downregulated and unaffected 
genes (Fig. 9a–c).
As previous reports suggested that FUS associates 
with RNAPII-CTD and P-TEFb, we tested the effects of 
FUS KO on the assembly of the elongation complex—P-
TEFb/SEC, RNAPII in J-LTR-Luc-FUS KO (Additional 
file  1: Figure S4), and compared it to that of J-LTR-Luc 
wild-type cells. By employing IP experiments with either 
Ser2 or Ser5 antibodies that target the different phospho-
rylated forms of the CTD of RNAPII, we demonstrated 
that as expected FUS associated with RNAPII, Cdk9 and 
AFF4/SEC in J-LTR-Luc cells. However, depletion of FUS 
had no effects on the association of RNAPII with P-TEFb 
and AFF4/SEC FUS KO cells, implying that the protein 
complex is assembled regardless of FUS recruitment 
to TSSs (Additional file  1: Figure S4). Furthermore, 
our results show that FUS associates both with Ser2 of 
RNAPII [54], and also with Ser5 of RNAPII, implying 
that FUS associates with the transcription machinery 
when the CTD is phosphorylated both on Ser5 and Ser2 
(Additional file 1: Figure S4). Finally, gene ontology (GO) 
analysis of genes that were affected by FUS KD found 
that genes that were upregulated are involved in impor-
tant cellular processes including cellular translational 
elongation, metabolism, mRNA splicing, RNA processing 
as well regulatory pathways of RNA. Interestingly, within 
the downregulated genes include negative regulation of 
transcription from RNAPII, demonstrating the linkage 
between FUS and the transcription machinery (Addi-
tional file 1: Figure S5).
Discussion
Pivotal work on the mechanisms that control HIV gene 
transcription elongation has paved the way to our under-
stating of how metazoan global gene transcription is exe-
cuted [1, 11, 12]. Based on this work, the role of SEC and 
P-TEFb in promoting RNAPII pause-release and elonga-
tion of transcription has been well documented [5, 8, 16]. 
In the unique case of HIV, the viral Tat protein acts as a 
master regulator of transcription elongation and recruits 
the cellular elongation machinery to the viral promoter 
to enhance pause-release of RNAPII and transcription 
elongation [11, 12, 38]. Elucidating the role of SEC/P-
TEFb in controlling HIV gene transcription is also of a 
high clinical significance, as transcription repression of 
the integrated provirus, mainly in resting CD4+ infected 
cells, results in the establishment and maintenance of the 
latent viral reservoir that is highly stable and refractory 
to anti-retroviral therapy. However, despite substantial 
progress in understanding the molecular mechanism 
that control HIV transcription and viral latency, a com-
plete eradication of the cell infected reservoir is still out 
of reach and the role of SEC in modulating this state is 
yet to be defined.
In this work we identify FUS as a regulator of HIV 
transcription. FUS associates with AFF4 of SEC in cells 
and silences viral gene transcription (Figs.  1, 2, 3). We 
could not demonstrate direct interactions between FUS 
and AFF4 proteins, and hypothesize that FUS resides in 
the elongation complex together with RNAPII, P-TEFb 
and SEC. Upon ectopic expression, FUS inhibits Tat-
independent HIV gene transcription. FUS also silences 
Tat-mediated HIV gene transcription, but to a lesser 
extent, implying that Tat is a more potent activator that 
efficiently recruits that transcription machinery. Nev-
ertheless, the overall fold of activation of transcription 
by Tat has not changed upon expression of FUS due its 
observed decrease in basal Tat-independent transcription 
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in the presence of FUS. Reversed effects on HIV gene 
transcription are also shown upon FUS depletion, which 
leads to enhancement of viral gene transcription (Fig. 4). 
However, activation of viral gene transcription follow-
ing FUS depletion is detected only in the absence of Tat, 
while upon Tat expression HIV transcription already 
reaches optimal levels despite of FUS knockout (Fig. 4). 
These results confirm the efficiency of Tat in enhancing 
HIV transcription elongation. They are also consistent 
with our previous report demonstrating that SEC pro-
motes Tat-independent transcription, while in the pres-
ence of Tat, SEC/P-TEFb are also recruited by the viral 
trans-activator to the promoter [72]. The mechanisms 
by which FUS is recruited to gene promoters and medi-
ates its effects are still largely unclear. Previous reports 
indicate that FUS associates with the CTD of RNAPII 
in an RNA-dependent manner [54]. Our experiments 
that demonstrate that a FUS mutant that cannot bind 
RNA (FUS-SGG4) has no inhibitory effects on HIV tran-
scription (Fig. 3) coincide with early reports stating that 
the RRM/RGG of FUS is required for FUS role in gene 
transcription and splicing [73]. Moreover, we show that 
association of the FUS-SGG4 mutant with TAR RNA is 
reduced relative to the wild type FUS (Additional file 1: 
Figure S2). Supporting this role of the FUS RNA motif, 
in a delta TAR HIV promoter, FUS occupancy on the 
viral promoter is also decreased (Fig.  6). Accordingly, 
our results conclude that FUS-mediated silencing is 
potentially promoted through inhibition of SEC/P-TEFb 
Fig. 9 Occupancy levels of AFF4 are elevated at genes that are upregulated upon FUS depletion. a + b AFF4 and Cdk9 ChIP-seq occupancy dataset 
from untreated cells focusing on genes that are affected due to loss of FUS expression (see also Additional file 1: Figure S3 for RNA seq). For each of 
the indicated windows, reads of Cdk9 or AFF4 were determined. *p < 0.0001 from Kruskal–Wallis test. c Fold of change in Cdk9 ChIP-seq reads within 
genes that were affected upon FUS depletion
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recruitment to the viral promoter and is dependent on 
RNA.
An additional possible mechanism for FUS effects 
would argue that the observed co-localization distribu-
tion of FUS and AFF4 within nuclear condensates, phase 
separated structures, might sequester the transcrip-
tion machinery from gene promoters and subsequently 
silence transcription (Fig.  8) [50, 52, 74–76]. Previous 
reports show that such a mechanism exists for hetero-
chromatin protein 1α and leads to chromatin compaction 
and transcription repression [77, 78]. Nuclear condensa-
tion of the polycomb repressive complex (PRC1)—CBX2 
represses transcription, as it undergoes phase separation 
to form nuclear structures that exhibit liquid-like proper-
ties and [79]. Our data imply that AFF4 and FUS exhibit 
granular expression pattern similar to phase separation 
structures. Moreover, both protein co-localize in the 
nucleus. AFF4-FUS punctuated structures potentially 
possess liquid phase separation properties, as treating 
cells with hexanediol, which dissolves the hydropho-
bic interactions within phase separation organelles, dis-
rupted the granular expression pattern of FUS, and AFF4, 
and led to protein migration into the cytoplasm (Fig. 8). 
As FUS is known to accumulate within phase separa-
tion structures, our working model implies that it limits 
the occupancy of AFF4 and subsequently SEC on gene 
promoters, leading to transcription silencing. The RNA 
binding activity of FUS is required for this effect of FUS, 
and current experiments investigate this hypothesis also 
in vitro.
Effects of FUS on HIV gene transcription are also dis-
played genome wide. Like in the case of HIV, FUS is glob-
ally positioned on TSSs of gene promoters. Interestingly, 
FUS also occupies exons and intergenic loci (Additional 
file 1: Figure S3), and current studies aim to analyze the 
role of FUS in modulating transcription of non-coding 
genes. Moreover, FUS globally affects SEC and P-TEFb 
occupancy, and in genes that are affected due to FUS 
knockdown, this occupancy is elevated relative to genes 
that are not-affected due to FUS depletion (Fig. 9; Addi-
tional file 1: Figure S3). Nevertheless, FUS knockout does 
not affect the assembly of the transcription machin-
ery, and we show that it can associate with the CTD of 
RNAPII both at its Ser5 or Ser2 forms, implying a role 
of FUS both at initiation or elongation of transcription 
(Additional file 1: Figure S4).
Finally, the eradication of the latent HIV reservoir 
remains a main obstacle towards a complete cure for 
infection. One current approach to successfully eradi-
cate the latent reservoir is to reactivate HIV gene expres-
sion in latently infected cells, and eliminate the active 
virus by HAART. To efficiently accomplish this “Shock 
and Kill” approach, the mechanisms that regulate HIV 
latency need to be fully understood, and host factors that 
modulate viral transcription have to be identified. Based 
on such studies, new drugs will be developed and will 
be combined with other already established regimens to 
optimally activate HIV gene expression. Our research 
shows that FUS regulates HIV latency by delaying the 
establishment of HIV latency state (Fig. 7). Importantly, 
we also demonstrate that FUS depletion enhances the 
reactivation of latent infected cells that is exhibited fol-
lowing treatment of cells with JQ1 (Fig. 7). We conclude 
that in our search for optimal protocols that reactivate 
the virus from its latent state with minimal global cell 
activation, targeting FUS expression should be con-
sidered as a potential therapeutic strategy that can be 
included with current regimens for battling HIV latency 
[38, 80].
Conclusions
In this work, we identified FUS as a partner of the AFF4 
subunit of SEC. We show that FUS assembles into the 
transcription machinery and regulates viral transcrip-
tion from the viral promoter. FUS silences viral gene 
expression and modulates HIV latency by disrupting 
the recruitment of AFF4/P-TEFb to the viral promoter. 
Expression patterns of FUS and AFF4 within nuclear 
condensate assemblies within cells, may provide an addi-
tional mechanism for the role of FUS is mediating gene 
silencing through sequestering SEC from the HIV pro-
moter and repressing gene transcription. These effects 
of FUS find their way in modulation of HIV latency, as 
in T cell latency models, we show that knockout of FUS 
delays the establishment of viral latency and enhances 
HIV gene activation upon treatment with JQ1. As we aim 
to eradicate the virally infected reservoir, understanding 
the molecular mechanisms that establish and maintain 
latency is of high clinical relevance. We propose that FUS 
can be considered a key factor in this process and a target 
for intervention, as we try to develop new strategies to 
eliminate HIV infection.
Materials and methods
Cells
Human Embryonic Kidney HEK293T (ATCC; 
CRL11268) that used for MS analysis were maintained 
in DMEM complete medium (GIBCO). Jurkat T lym-
phocytes cell line were maintained in RMPI medium 
(GIBCO), supplemented with 10% fetal bovine serum, 
2  mg/ml  l-glutamine, penicillin–streptomycin, and 
non-essential amino acids (Sigma, M7145). Cells were 
cultured at 37  °C with 5% CO2. J-LTR-Luc cells were 
generated by transducing Jurkat cells with VSV-G psue-
dotyped lentivirus that encodes LTR-Luciferase (Luc) 
reporter gene. To generate-LTR-Tat-Luc cells, J-LTR-Luc 
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cells were further transduced with a lentivirus encoding 
HA-Tat lentivirus and the blue fluorescent protein (BFP) 
under the control of the HIV LTR promoter. Clonal pop-
ulation was obtained after sorting single cells expressing 
BFP by FACS. To ectopically express FUS, the indicated 
cells were transduced with a lentivirus encoding the for 
Flag-FUS under the CMV promoter, followed by puro-
mycin selection. 2D10 are Jurkat T cells that express HIV-
LTR-2dGFP and represent latent cell model as described 
in the text [66].
Plasmids
FUS expression plasmid was described previously [54]. 
FUS cDNA was sub-cloned as a Flag-tagged protein in 
pCDNA3, or into a lentiviral vector. For analysis of HIV 
gene transcription, lentiviral vector expressing the Lucif-
erase Protein under the LTR promoter (HIV-LTR-Luc) 
reporter, regulated by HIV-LTR-was used. HA-AFF4 
expression plasmid was a generous gift from Dr. Qiang 
Zhou laboratory—University of California, Berkeley. 
HA-AFF4 was sub-cloned into a lentiviral vector harbor-
ing N-terminal HA-tag. Constructs for truncated HA-
AFF4 proteins were generated by PCR amplification of 
the desired length of AFF4 cDNA, using an N-terminal 
primer and primers located at the C-terminus region. 
CRISPR/Cas9 expression plasmids were obtained from 
Addgene (#49535).
Production of VSV‑G pseudotyped lentiviruses
Single round viral particles were produced by calcium 
phosphate-mediated co-transfection of the lentivec-
tor expressing the pLTR-Luciferase, and plasmids cod-
ing for HIV structural and regulatory genes (gag/pol, 
Rev, Tat) and VSV-G envelope into packaging cell line 
Human Embryo Kidney HEK 293T. Viral particles were 
harvested from culture supernatant 48  h post transfec-
tion, spun at 2000 rpm for 10 min to remove cell debris, 
and filtered through 0.45  μm filter (Amicon). Lentiviral 
particles were concentrated by ultra-centrifugation for 
2.5 h at 25,000 rpm, (Beckman OptimaL 90 K ultracen-
trifuge, SW-28 rotor) and the pellet was re-suspended in 
PBS. Titer of lentiviruses encoding for the Luc reporter 
was determined by transduction of Jurkat cells with serial 
dilutions of the virus stock followed by Luc reporter 
assays.
Lentiviral transduction and luciferase reporter assays
Cells were transduced with VSV-G pseudotyped len-
tivirus expressing the HIV-LTR luciferase transgene. 
Similarly, lentivirus that express FUS or Cas9/sgRNA 
were used for transduction. 48 h post transduction, cells 
were harvested and their luciferase activity was meas-
ured according to the manufacture manual (Promega). 
Luciferase readings were normalized to protein expres-
sion or to Renila as an internal control, and are presented 
relative to the readings obtained in parental Jurkat cells—
set to 1. Results are presented as the mean value of tripli-
cate wells; error bars show ± SEM.
CRISPR‑mediated gene silencing
J-LTR-Luc cells were transduced with lentivirus encod-
ing Cas9 and each of two different sgRNAs that target 
FUS (Addgene #49535). A mixture of the two guides were 
transduced. As a control, cells were also transduced with 
the same Cas9 encoding virus where a scranbled sgRNA 
was cloned. Following lentiviral transduction, cells were 
cultured with media supplemented with 1 μg/ml of puro-
mycin to eliminate non-transduced cells. Single puromy-
cin resistant clones were obtained by serial dilution in a 
96 well and further expanded. Clones were genotyped to 
confirm gene editing, and depletion of FUS expression 
was further confirmed by western blotting analysis with 
specific anti-FUS antibody (4H11; Santa Cruz Biotech-
nology #47711). Two different clones of cells that nega-
tively express FUS (J-LTR-Luc FUS KO #1 and #11) were 
functionally analyzed. Western blot analysis with anti-
Tubulin antibody confirmed equal loading of protein.
Purification of HA‑AFF4 associating proteins from cells
HEK293T cells were grown on 10 cm culture dishes and 
were transfected with 10  μg of HA-AFF4 (Full length, 
300 residues) using Lipofectamin2000. 2 μg of a plasmid 
expressing a GFP reporter gene was also co-transfected 
for measuring transfection efficiency. 48  h post trans-
fection, 2 × 109 HEK 293T cells expressing HA-tagged 
AFF4 proteins were harvested and lysed with optimized 
IP buffer (500 μl; 0.15% Triton X-100; 20 mM Tris–HCl-
pH 7.6; 200 mM NaCl; 0.72 mM EDTA and 10% Glycerol; 
supplemented with protein inhibitor cocktail—added 
fresh before use and phosphatase inhibitors: 6  mM of 
NaF and 2 mM of  Na2VO4). Cell lysates were then incu-
bated for 1  h on ice before centrifuged 14,000  rpm for 
5 min at 4 °C. Supernatant was then collected and cleared 
with protein A Sepharose beads before incubation with 
5 μg of anti-HA antibody (Abcam) overnight at 4 °C with 
gentle rocking. The next day, lysates were incubated with 
50  μl of pre-blocked protein A beads were added to IP 
samples and incubated on a rocker for additional 2 h at 
4 °C. Beads were washed × 4 times with the IP buffer sup-
plemented with 0.1% Triton X-100 and centrifuged for 
3 min at 3000 rpm at 4 °C. 5% of the eluate was resolved 
on SDS-PAGE and proteins were visualized by silver 
staining using a Silverquest kit (Invitrogen). The remain-
ing eluate was resolved on SDS-PAGE, then stained with 
Coomassie-R250. Individual Coomassie-R250 stained 
bands were excised and proteins in gels digested with 
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sequencing grade trypsin according to the manufacturer’s 
protocol (Promega). Excised gel pieces were first washed 
with 50% acetonitrile in 50 mM ammonium bicarbonate, 
and then dehydrated with acetonitrile. Proteins were 
then subjected to overnight proteolytic digestion (after 
reduction in 20  mM DTT at room temperature for 2  h 
and alkylation with 50  mM iodoacetamide in 50  mM 
ammonium, bicarbonate for 1 h in the dark), followed by 
extraction from the gel with 5% formic acid in 50% ace-
tonitrile and then re-suspended in 0.1% formic acid after 
being dried under vacuum. Samples were then analyzed 
by tandem Mass Spectrometry at BGU Nanotechnology 
facility.
LC/MS analysis of the protein digests was performed 
using an Eksigent nano‐HPLC (model nanoLC-2D, 
Netherlands)  connected to the LTQ Orbitrap XL ETD 
(Thermo Fisher Scientific, Germany and USA). Reverse‐
phase chromatography of peptides was performed using 
homemade C‐18 column (15 cm long, 75 μm ID) packed 
with Jupiter C18, 300 Å, 5 μm beads (Phenomenex). Pep-
tides were separated by a 70‐min linear gradient, starting 
with 100% buffer A (5% acetonitrile, 0.1% formic acid) 
and ending with 80% buffer B (80% acetonitrile, 0.1% 
formic acid), at a flow rate of 300  nl/min. A full scan, 
acquired at 60,000 resolution, was followed by CID MS/
MS analysis performed for the five most abundant peaks, 
in the data‐dependent mode. Fragmentation (with mini-
mum signal trigger threshold set at 500) and detection of 
fragments were carried out in the linear ion trap. Maxi-
mum ion fill time settings were 500 ms for the high‐reso-
lution full scan in the Orbitrap analyzer and 200 ms for 
MS/MS analysis in the ion trap. The AGC settings were 
5 × 105 and 1 × 104 (MS/MS) for Orbitrap and linear ion 
trap analyzers, respectively. Proteins were identified and 
validated using the SEQUEST and Mascot search engine 
operated under the Proteome Discoverer 1.4 software 
(Thermo Fisher Scientific) Mass tolerance for precur-
sors and fragmentations was set to 10  ppm and 0.8  Da, 
respectively. Only proteins containing at least two pep-
tides of high confidence (Xcore N 2 or 2.5 for doubly or 
triply charged species, respectively) were chosen.
Immunoprecipitation in cells
For mapping the regions in AFF4 that interact with FUS, 
HEK293T cells were transfected with plasmids encod-
ing Flag-FUS and the each of the indicated HA-AFF4 
C-terminal truncated proteins. Cells were then harvested 
and lysed with 500  μl lysis buffer (0.15% Triton X-100; 
20 mM Tris–HCl pH 7.6; 200 mM NaCl; 0.72 mM EDTA; 
10% Glycerol; 1  mM DTT, supplemented with protease 
inhibitors cocktail (Sigma; 1:200 dilution). Lysates were 
pre-cleared with Protein A-Sepharose beads (Invitro-
gen) and then incubated on ice for 1 h and centrifuged at 
14,000 rpm for 10 min at 4 °C. Cleared supernatants were 
then incubated overnight with gentle rocking with 1 μg of 
anti-HA antibody (Abcam #9110). 50 μl was taken of the 
lysis before the addition of anti-HA antibody for input 
analysis. Expression levels of Flag-FUS were monitored 
with the anti-Flag antibody (M2-Sigma; A2220).
Cell‑based latency assays
J-LTR-Luc cells or cells where FUS expression was 
depleted (J-LTR-Luc FUS KO) were infected at day 0 with 
pseudotyped HIV-GFP virus (pHR-GFP HIV). Cells were 
then sorted for their GFP expression and further cultured 
for the indicated time days post infection to gradually 
enter latency. GFP expression was monitored in control 
or FUS KO cells at the indicated time points. To ensure 
that cells in the pooled population harbor latent provirus. 
Cells at day 60 post infection were analyzed by FACS, and 
the GFP(−) expressing cells were sorted and treated with 
JQ1. 2D10 T cells were transfected with either control 
scramble siRNA or siRNA specific against FUS (synthe-
sized by IDT) by Neon electroporation system (Thermo). 
Following transfection of cells, growth media was 
changed and let grow for additional 72  h post transfec-
tion. Cells were stimulated with JQ1 at the indicted con-
centration for 24 h and GFP expression was monitored by 
FACS. Specific HIV RNA was also extracted from control 
and FUS KD 2D10 cells and was monitored by quantita-
tive PCR (qPCR) using specific primers positioned on 
Gag (non-spliced HIV mRNA) and Rev (multiply spliced 
HIV mRNA).
Rev primers were used as described [81].
Forward GAA GAA GAA GGT GGA GAG AGA GAC .
Reverse TGT AGC AAG CTC GAT GTC AGC AGT .
Gag primers were also previously described [82].
Chromatin immunoprecipitation analysis (ChIP) qPCR 
analysis
J-LTR-Luc and J-LTR-Luc FUS KO cells were cross-
linked with 1% formaldehyde for 10  min, and after 
washing with PBS, cross-linking was stopped by add-
ing glycine (0.125  M; 5  min). Cells were then lysed 
for 10  min on ice in 500  μl lysis buffer (50  mM HEPES 
pH-7.5, 140  mM NaCl, 1% Triton X-100, 1  mM EDTA, 
0,1% SDS and 1% protease inhibitor cocktail;) and the 
nuclear pellets were collected. DNA was fragmented by 
sonication with the following settings: amplitude 40%, 
for 10 cycles 20  s on/40  s off)Sonics Vibra Cell(. Sam-
ples were centrifuged (15  min, 14,000  rpm, 4  °C) and 
the soluble chromatin fraction (50 μg) was collected and 
immune-precipitated overnight with either anti-FUS 
IgG (5  μg), anti-HA IgG or anti-Cdk9 IgG. Precipitated 
DNA fragments were extracted with phenol–chloroform 
and quantified by qPCR with the primers specific to the 
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LTR promoter (Forward:_5′—AGG TTT GAC AGC CGC 
CTA -3; Reverse: AGA GAC CCA GTA CAG GCA AAA). 
All signals were normalized relative to the input DNA. 
ChIP assays were also performed with normal rabbit or 
mouse IgG as negative controls. Methods for the whole-
genome ChiP-Seq and RNA-seq analysis are described in 
the Additional files.
Live‑cell imaging
HEK293T cells were grown in 1 cm gelatin coated micro-
slides and transfected 0.1  μg expression plasmids. Prior 
to imaging, cells were sorted for low GFP/BFP expression 
to eliminate over expression effects on protein localiza-
tion. 48 h post transfection hexanediol was added to the 
medium to reach a final concentration of 15% for 2 min 
and thereafter cells were washed and media was added. 
Live imaging was taken with FV1000 confocal micro-
scope (Olympus) at magnification of X60. Nuclease stain-
ing was performed using DraQ5 dye (Thermo Fisher), 
diluted 1/1000 in PBS.
Additional files
Additional file 1. Supporting results.
Additional file 2. Summary of MS analysis - HA-HFF4-full-length.
Additional file 3. Sumamry of MS analysis - HA-HFF4-(1-300).
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